ChemExpress focuses on small molecule drug research and development services. For ADC development, we focus on the process development and scaling up of payloads, linkers, toxins of all kinds. We independently developed the process for MC-Val-Cit-PAB-Auristatin E, and worked with Remegen to successfully develop Disitamab Vedotin. Over 500 different kinds of linkers and payloads have been made available in-stock. Our CDMO service covers custom synthesis, scaling-up, process validation, DMF registration, CMC management, and IND filing